Connect with us

Technology

ELBIT SYSTEMS REPORTS THIRD QUARTER 2024 RESULTS

Published

on

Order backlog at $22.1 billion; Revenues of $1.7 billion;
Non-GAAP net income of $99 million; GAAP net income of $79 million;
Non-GAAP net EPS of $2.21; GAAP net EPS of $1.77 

HAIFA, Israel, Nov. 19, 2024 /PRNewswire/ — Elbit Systems Ltd. (“Elbit Systems” or the “Company”) (NASDAQ: ESLT) (TASE: ESLT), the international high technology defense company, reported today its consolidated results for the third quarter ended September 30, 2024.

In this release, the Company is providing US-GAAP results as well as non-GAAP financial data, which are intended to provide investors a more comprehensive view of the Company’s business results and trends. For a description of the Company’s non-GAAP definitions see page 4 below, “Non-GAAP financial data”. Unless otherwise stated, all financial data presented is US-GAAP financial data.

Management Comment:

Bezhalel (Butzi) Machlis, President and CEO of Elbit Systems, commented: 

“Elbit Systems reports a strong quarter, with substantial growth across key performance measures exceeding our internal goals, while meeting our customers’ needs in Israel and worldwide. The Company’s order backlog, which hit a record high of over $22 billion, provides stability and resilience for the Company for years to come, as our investments in R&D create strong foundations for long-term growth and development. Our highly regarded solutions and products are experiencing high demand. This consistent growth reflects the quality and excellence driven by our dedicated and outstanding employees in Israel and in our subsidiaries around the world.”

Third quarter 2024 results:

Revenues in the third quarter of 2024 were $1,717.5 million, as compared to $1,501.6 million in the third quarter of 2023.

Aerospace revenues increased by 7% in the third quarter of 2024, as compared to the third quarter of 2023 mainly due to increased UAS sales in Israel. C4I and Cyber revenues increased by 13% in the third quarter of 2024 mainly due to radio systems and command and control systems sales. ISTAR and EW revenues increased by 13% mainly due to Electronic Warfare and Electro-Optic systems sales. Land revenues increased by 24% due to the increase in ammunition and munition sales in Israel. Elbit Systems of America revenues increased by 17% due to the increase in night-vision systems and medical instrumentation sales.

For distribution of revenues by segments and geographic regions see the tables on page 12.

Non-GAAP(*) gross profit amounted to $419.4 million (24.4% of revenues) in the third quarter of 2024, as compared to $374.2 million (24.9% of revenues) in the third quarter of 2023. GAAP gross profit in the third quarter of 2024 was $412.8 million (24.0% of revenues), as compared to $367.2 million (24.5% of revenues) in the third quarter of 2023.

Research and development expenses, net were $119.9 million (7.0% of revenues) in the third quarter of 2024, as compared to $103.3 million (6.9% of revenues) in the third quarter of 2023.

Marketing and selling expenses, net were $91.3 million (5.3% of revenues) in the third quarter of 2024, as compared to $86.0 million (5.7% of revenues) in the third quarter of 2023.

General and administrative expenses, net were $75.7 million (4.4% of revenues) in the third quarter of 2024, as compared to $71.8 million (4.8% of revenues) in the third quarter of 2023.

Non-GAAP(*) operating income was $140.7 million (8.2% of revenues) in the third quarter of 2024, as compared to $120.0 million (8.0% of revenues) in the third quarter of 2023. GAAP operating income in the third quarter of 2024 was $125.8 million (7.3% of revenues), as compared to $106.1 million (7.1% of revenues) in the third quarter of 2023.

Financial expenses, net were $45.0 million in the third quarter of 2024, as compared to $35.7 million in the third quarter of 2023.

Taxes on income were $12.8 million in the third quarter of 2024, as compared to $10.0 million in the third quarter of 2023.

Non-GAAP(*) net income attributable to the Company’s shareholders in the third quarter of 2024 was $98.8 million (5.8% of revenues), as compared to $76.5 million (5.1% of revenues) in the third quarter of 2023. GAAP net income attributable to the Company’s shareholders in the third quarter of 2024 was $79.1 million (4.6% of revenues), as compared to $60.7 million (4.0% of revenues) in the third quarter of 2023.

Non-GAAP(*) diluted net earnings per share attributable to the Company’s shareholders were $2.21 for the third quarter of 2024, as compared to $1.71 for the third quarter of 2023. GAAP diluted earnings per share attributable to the Company’s shareholders in the third quarter of 2024 were $1.77, as compared to $1.36 in the third quarter of 2023.

The Company’s order backlog as of September 30, 2024 totaled $22.1 billion. Approximately 66% of the current backlog is attributable to orders from outside Israel. Approximately 37% of the backlog is scheduled to be performed during the remainder of 2024 and 2025. 

Cash flow provided by operating activities in the nine months ended September 30, 2024 was $82.5 million, as compared to cash flow used in operating activities of $200.0 million in the nine months ended September 30, 2023. The cash flow in the nine months ended September 30, 2024 was affected mainly by the increase in contract liabilities, which was offset by the increase in inventories and trade receivables.

__________                    

* see page 4

Impact of the “Swords of Iron” War on the Company:

On October 7, 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of brutal attacks on civilian and military targets. Hamas also launched extensive rocket attacks on the Israeli population and industrial centers located along Israel’s border with the Gaza Strip and on many other parts of the country. Israel has also been attacked by other terrorist organizations on different fronts, including from Lebanon, which have prompted military responses from Israel on these fronts. Following the attacks, the State of Israel declared a state of war, which is ongoing.

Since the commencement of hostilities, Elbit Systems has experienced a material increased demand for its products and solutions from the Israel Ministry of Defense (IMOD) compared to the demand levels prior to the war. The Company has also increased its support to the IMOD, mainly through deliveries of its systems and the dedicated efforts of our employees. At the same time, the Company continues its activities in the international markets with the support of its local subsidiaries. Subject to further developments, which are difficult to predict, the IMOD’s increased demand for the Company’s products and solutions may continue and could generate material additional orders for the Company.

While the vast majority of the facilities in Israel continue to operate uninterrupted, some operations have experienced disruptions due to supply chain and operational constraints, including among others due to limitations on exports to Israel, increase of transportation costs and delays, material and component shortages, attacks by anti-Israeli organizations, the relocation of certain production lines, evacuation of employees and employee recruitment for reserve duty. The number of employees recruited was approximately 8% as of September 30, 2024, and could fluctuate depending on future developments.

Elbit Systems has taken a number of steps to protect the safety and the security of its employees in Israel and abroad, to support its increased production, to mitigate existing and potential supply chain disruptions and to maintain business continuity, including the relocation of production lines from facilities in evacuated areas to alternative facilities; recruitment of additional employees; increased monitoring of global supply chains to identify delays, shortages and bottlenecks; rescheduling of deliveries to certain customers as necessary; and an increase of inventories.

The extent of the effects of the war on the Company’s performance will depend on future developments of the war that are difficult to predict at this time, including its duration and scope. We continue to monitor the situation closely.

* Non-GAAP financial data:

The following non-GAAP financial data, including Adjusted gross profit, Adjusted operating income, Adjusted net income, and Adjusted diluted earnings per share, is presented to enable investors to have additional information on our business performance as well as a further basis for periodical comparisons and trends relating to our financial results. We believe such data provides useful information to investors and analysts by facilitating more meaningful comparisons of our financial results over time. The non-GAAP adjustments exclude amortization expenses of intangible assets related to acquisitions that occurred mainly in prior periods, capital gains related primarily to the sale of investments, restructuring activities, uncompensated costs related to “Swords of Iron” war, non-cash stock based compensation expenses, revaluations of investments in affiliated companies, non-operating foreign exchange gains or losses, one-time tax expenses, and the effect of tax on each of these items. We present these non-GAAP financial measures because management believes they supplement and/or enhance management’s, analysts’ and investors’ overall understanding of the Company’s underlying financial performance and trends and facilitate comparisons among current, past, and future periods.

Specifically, management uses Adjusted gross profit, Adjusted operating income, and Adjusted net income attributable to the Company’s shareholders to measure the ongoing gross profit, operating profit and net income performance of the Company because the measure adjusts for more significant non-recurring items, amortization expenses of intangible assets relating to prior acquisitions, and non-cash expense which can fluctuate year to year.

We believe Adjusted gross profit, Adjusted operating income, and Adjusted net income attributable to the Company’s shareholders are useful to existing shareholders, potential shareholders and other users of our financial information because they provide measures of the Company’s ongoing performance that enable these users to perform trend analysis using comparable data.

Management uses Adjusted diluted earnings per share to evaluate further adjusted net income attributable to the Company’s shareholders while considering changes in the number of diluted shares over comparable periods.

We believe adjusted diluted earnings per share is useful to existing shareholders, potential shareholders and other users of our financial information because it also enables these users to evaluate adjusted net income attributable to Company’s shareholders on a per-share basis.

The non-GAAP measures used by the Company are not based on any comprehensive set of accounting rules or principles. We believe that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations, as determined in accordance with GAAP, and that these measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP measures.

Investors are cautioned that, unlike financial measures prepared in accordance with GAAP, non-GAAP measures may not be comparable with the calculation of similar measures for other companies. They should consider non-GAAP financial measures in addition to, and not as replacements for or superior to, measures of financial performance prepared in accordance with GAAP.

Reconciliation of GAAP to Non-GAAP Supplemental Financial Data:

(US Dollars in millions, except for per share amounts)

Nine
months
ended
September
30, 2024

Nine
months
ended
September
30, 2023

Three
months
ended
September
30, 2024

Three
months
ended
September
30, 2023

Year
ended
December
31, 2023

GAAP gross profit

$  1,176.6

$  1,100.8

$     412.8

$     367.2

$  1,483.0

Adjustments:

Amortization of purchased intangible assets(*)

14.8

20.2

4.2

6.6

27.3

Restructuring of a subsidiary’s activities

17.5

Stock based compensation

1.5

1.5

0.7

0.4

1.8

Uncompensated labor costs related to “Swords of Iron” war

6.0

1.7

4.3

Non-GAAP gross profit

$  1,198.9

$  1,122.5

$     419.4

$     374.2

$  1,533.9

Percent of revenues

24.5 %

25.8 %

24.4 %

24.9 %

25.7 %

GAAP operating income

$     347.7

$     301.5

$     125.8

$     106.1

$     369.1

Adjustments:

Amortization of purchased intangible assets(*)

26.5

32.7

8.1

10.9

43.9

Restructuring of a subsidiary’s activities

17.5

Stock based compensation

10.1

9.7

4.4

3.0

12.1

Uncompensated labor costs related to “Swords of Iron” war

8.6

2.4

6.1

Non-GAAP operating income

$     392.9

$     343.9

$     140.7

$     120.0

$     448.7

Percent of revenues

8.0 %

7.9 %

8.2 %

8.0 %

7.5 %

GAAP net income attributable to Elbit Systems’ shareholders

$     231.1

$     185.1

$        79.1

$        60.7

$     215.1

Adjustments:

Amortization of purchased intangible assets(*)

26.5

32.7

8.1

10.9

43.9

Restructuring of a subsidiary’s activities

17.5

Stock based compensation

10.1

9.7

4.4

3.0

12.1

Uncompensated labor costs related to “Swords of Iron” war

8.6

2.4

6.1

Capital gain

(2.0)

(2.0)

Revaluation of investment measured under fair value option

7.4

3.0

Non-operating foreign exchange (gains) losses

(4.2)

5.7

8.1

3.3

12.0

Tax effect and other tax items, net

(5.3)

(4.2)

(1.3)

(1.4)

(10.9)

Non-GAAP net income attributable to Elbit Systems’ shareholders   

$     272.2

$     229.0

$        98.8

$        76.5

$     298.8

Percent of revenues

5.6 %

5.3 %

5.8 %

5.1 %

5.0 %

GAAP diluted net EPS

$        5.18

$        4.15

$        1.77

$        1.36

$        4.82

Adjustments, net

0.92

0.99

0.44

0.35

1.88

Non-GAAP diluted net EPS

$        6.10

$        5.14

$        2.21

$        1.71

$        6.70

(*) While amortization of acquired intangible assets is excluded from the measures, the revenue of the acquired companies is reflected in the measures
and the acquired assets contribute to revenue generation.

 

Recent Events:

On September 20, 2024, the Company announced that at its Annual General Meeting of Shareholders held on September 19, 2024 at the Company’s offices in Haifa, each of the proposals described in the Proxy Statement to the shareholders dated August 15, 2024, was approved by the required majority.

On October 28, 2024, the Company announced that it was awarded an approximately $200 million contract by the Israeli Ministry of Defense to supply high-power laser systems for the “Iron Beam” air defense system.

On November 5, 2024, the Company announced that it was awarded a follow-on contract of approximately $127 million to supply Iron Fist Active Protection Systems to General Dynamics Ordnance and Tactical Systems for upgrades to the U.S. Army’s Bradley M2A4E1 Infantry Fighting Vehicles. The contract will be performed over a period of 34 months.

On November 18, 2024, the Company announced that it was awarded contracts worth a total amount of approximately $335 million, to supply defense systems to a European country. The contracts include the supply of PULS™ (Precise and Universal Launching Systems) rocket launchers and rockets, as well as Hermes™ 900 Unmanned Aircraft Systems equipped with advanced payloads. The contracts will be performed over a period of three years and six months.

Dividend:

The Board of Directors declared a dividend of $0.50 per share. The dividend’s record date is December 23, 2024. The dividend will be paid on January 6, 2025, after deduction of withholding tax, at the rate of 16.8%. 

Conference Call:

The Company will be hosting a conference call today, Wednesday, November 19, 2024, at 10:00 a.m. Eastern Time. On the call, management will review and discuss the results and will be available to answer questions.

To participate, please call one of the teleconferencing numbers that follow. If you are unable to connect using the toll-free numbers, please try the international dial-in number.

US Dial-in Number: 1-866-744-5399
Canada Dial-in Number: 1-866-485-2399
Israel Dial-in Number: 03-918-0644
International Dial-in Number: 972-3-918-0644

at 10:00am Eastern Time; 7:00am Pacific Time; 5:00pm Israel Time

The conference call will also be broadcast live on Elbit Systems’ website at https://www.elbitsystems.com. An online replay will be available from 24 hours after the call ends.

Alternatively, for two days following the call, investors will be able to dial a replay number to listen to the call. The dial-in numbers are: 1-888-782-4291 (US and Canada) or +972-3-925-5900 (Israel and International).

About Elbit Systems

Elbit Systems is a leading global defense technology company, delivering advanced solutions for a secure and safer world. Elbit Systems develops, manufactures, integrates and sustains a range of next-generation solutions across multiple domains.

Driven by its agile, collaborative culture, and leveraging Israel’s technology ecosystem, Elbit Systems enables customers to address rapidly evolving battlefield challenges and overcome threats.

Elbit Systems employs over 20,000 people in dozens of countries across five continents. The Company reported as of September 30, 2024 approximately $1.7 billion in revenues and an order backlog of approximately $22.1 billion.

For additional information, visit: https://elbitsystems.com/, follow us on Twitter or visit our official Facebook, Youtube and LinkedIn channels.

Attachments:

Consolidated balance sheets
Consolidated statements of income
Consolidated statements of cash flows
Consolidated revenue distribution by geographical regions and by segments

Company Contact:

Dr. Yaacov (Kobi) Kagan, EVP & Chief Financial Officer
Tel:  +972-77-2946663
kobi.kagan@elbitsystems.com 

Daniella Finn, VP, Investor Relations
Tel: +972-77-2948984
daniella.finn@elbitsystems.com 

Dalia Bodinger, VP, Communications & Brand
Tel: +972-77-2947602 
dalia.bodinger@elbitsystems.com      

 

This press release may contain forward–looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Israeli Securities Law, 1968) regarding Elbit Systems Ltd. and/or its subsidiaries (collectively the Company), to the extent such statements do not relate to historical or current facts. Forward-looking statements are based on management’s current expectations, estimates, projections and assumptions about future events. Forward–looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions about the Company, which are difficult to predict, including projections of the Company’s future financial results, its anticipated growth strategies and anticipated trends in its business. Therefore, actual future results, performance and trends may differ materially from these forward–looking statements due to a variety of factors, including, without limitation: scope and length of customer contracts; governmental regulations and approvals; changes in governmental budgeting priorities; general market, political and economic conditions in the countries in which the Company operates or sells, including Israel and the United States among others; including the duration and scope of the current war in Israel, and the potential impact on our operations; changes in global health and macro-economic conditions; differences in anticipated and actual program performance, including the ability to perform under long-term fixed-price contracts; changes in the competitive environment; and the outcome of legal and/or regulatory proceedings. The factors listed above are not all-inclusive, and further information is contained in Elbit Systems Ltd.’s latest annual report on Form 20-F, which is on file with the U.S. Securities and Exchange Commission. All forward–looking statements speak only as of the date of this release.

Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. The Company does not undertake to update its forward-looking statements.

Elbit Systems Ltd., its logo, brand, product, service and process names appearing in this Press Release are the trademarks or service marks of Elbit Systems Ltd. or its affiliated companies.  All other brand, product, service and process names appearing are the trademarks of their respective holders.  Reference to or use of a product, service or process other than those of Elbit Systems Ltd. does not imply recommendation, approval, affiliation or sponsorship of that product, service or process by Elbit Systems Ltd. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, copyright, trademark or other intellectual property right of Elbit Systems Ltd. or any third party, except as expressly granted herein.

(FINANCIAL TABLES TO FOLLOW)

 

ELBIT SYSTEMS LTD.

CONSOLIDATED BALANCE SHEETS

(In thousands of US Dollars)

As of

September 30, 2024

As of

December 31, 2023

Assets

Cash and cash equivalents

$                    119,199

$                    197,429

Short-term bank deposits

4,169

10,518

Trade and unbilled receivables and contract assets, net

3,055,619

2,716,762

Other receivables and prepaid expenses

363,002

285,352

Inventories, net

2,822,733

2,298,019

Total current assets

6,364,722

5,508,080

Investments in affiliated companies and other companies

133,784

145,350

Long-term trade and unbilled receivables and contract assets

458,898

364,719

Long-term bank deposits and other receivables

41,435

87,648

Deferred income taxes, net

23,765

23,423

Severance pay fund

204,724

206,943

Total

862,606

828,083

Operating lease right of use assets

527,943

425,884

Property, plant and equipment, net

1,232,948

1,087,950

Goodwill and other intangible assets, net

1,858,870

1,889,585

Total assets

$              10,847,089

$                 9,739,582

Liabilities and Equity

Short-term bank credit and loans

$                    689,292

$                    576,594

Current maturities of long-term loans and Series B, C and D Notes

74,547

75,286

Operating lease liabilities

78,586

67,390

Trade payables

1,310,636

1,254,126

Other payables and accrued expenses

1,264,973

1,194,347

Contract liabilities

2,129,874

1,656,103

Total current liabilities

5,547,908

4,823,846

Long-term loans, net of current maturities

29,574

41,227

Series B, C and D Notes, net of current maturities

274,902

342,847

Employee benefit liabilities

499,656

510,416

Deferred income taxes and tax liabilities, net

62,464

55,240

Contract liabilities

618,546

354,319

Operating lease liabilities

451,930

363,100

Other long-term liabilities

288,863

298,296

Total long-term liabilities

2,225,935

1,965,445

Elbit Systems Ltd.’s equity

3,069,810

2,947,503

Non-controlling interests

3,436

2,788

Total equity

3,073,246

2,950,291

Total liabilities and equity

$              10,847,089

$                 9,739,582

 

 

ELBIT SYSTEMS LTD.

CONSOLIDATED STATEMENTS OF INCOME

(In thousands of US Dollars, except for share and per share amounts)

Nine months
ended
September 30,
2024

Nine months
ended
September 30,
2023

Three months
ended
September 30,
2024

Three months
ended
September 30,
2023

Year ended
December 31,
2023

Revenues

$     4,897,655

$     4,348,950

$     1,717,547

$     1,501,567

$     5,974,744

Cost of revenues

3,721,036

3,248,104

1,304,763

1,134,393

4,491,790

Gross profit

1,176,619

1,100,846

412,784

367,174

1,482,954

Operating expenses:

Research and development, net

335,210

307,065

119,890

103,315

424,420

Marketing and selling, net

268,144

267,845

91,349

85,967

359,141

General and administrative, net

225,608

224,406

75,736

71,842

330,285

Total operating expenses

828,962

799,316

286,975

261,124

1,113,846

Operating income

347,657

301,530

125,809

106,050

369,108

Financial expenses, net

(105,219)

(91,991)

(44,953)

(35,722)

(137,827)

Other income (expenses), net

10,269

(5,375)

7,002

(1,851)

(4,787)

Income before income taxes

252,707

204,164

87,858

68,477

226,494

Taxes on income

(35,689)

(27,957)

(12,830)

(10,014)

(22,913)

Income after taxes on income

217,018

176,207

75,028

58,463

203,581

Equity in net earnings of affiliated companies

14,625

9,247

4,284

2,395

12,275

Net income

$        231,643

$        185,454

$          79,312

$          60,858

$        215,856

Less: net income attributable to non-controlling interests

(498)

(331)

(206)

(155)

(725)

Net income attributable to Elbit Systems Ltd.’s shareholders

$        231,145

$        185,123

$          79,106

$          60,703

$        215,131

Earnings per share attributable to Elbit Systems Ltd.’s shareholders:

Basic net earnings per share

$               5.20

$               4.17

$               1.78

$               1.37

$              4.85

Diluted net earnings per share

$               5.18

$               4.15

$               1.77

$               1.36

$             4.82

Weighted average number of shares used in computation of:

Basic earnings per share (in thousands)

44,472

44,351

44,478

44,360

44,375

Diluted earnings per share (in thousands)

44,633

44,579

44,618

44,642

44,592

 

 

ELBIT SYSTEMS LTD.

CONSOLIDATED STATEMENTS OF CASH FLOW

(In thousands of US Dollars)

Nine months
ended
September 30,
2024

Nine months
ended
September 30,
2023

Year ended
December 31,
2023

CASH FLOWS FROM OPERATING ACTIVITIES

Net income

$         231,643

$         185,454

$         215,856

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

117,145

123,477

164,799

Stock-based compensation

10,060

9,732

12,141

Amortization of series B, C and D related issuance costs, net

358

445

579

Deferred income taxes and reserve, net

12,124

4,025

(13,165)

Gain on sale of property, plant and equipment

(419)

(241)

(651)

Loss on sale of investment, remeasurement of investments held under fair value method

6,079

6

4,990

Equity in net (earnings) losses of affiliated companies, net of dividend received (*)

(6,085)

5,060

10,046

Changes in operating assets and liabilities, net of amounts acquired:

Increase in trade and unbilled receivables and prepaid expenses

(466,738)

(65,444)

(96,594)

Increase in inventories, net

(529,345)

(345,201)

(351,594)

Increase (decrease) in trade payables and other payables and accrued expenses

(1,726)

30,999

175,446

Severance, pension and termination indemnities, net

(28,734)

(20,892)

(24,331)

Increase (decrease) in contract liabilities

738,177

(127,451)

16,187

Net cash (used in) provided by operating activities

82,539

(200,031)

113,709

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of property, plant and equipment and other assets(***)

(167,002)

(157,787)

(187,037)

Acquisition of subsidiaries, net of cash assumed

(10,380)

(10,380)

Investments in affiliated companies and other companies, net

(3,151)

(2,939)

(5,416)

Proceeds from sale of property, plant and equipment

5,013

600

1,466

Proceeds from sale of a subsidiary and an investments

24,776

151

Investment in short-term deposits, net

7,068

(25,576)

(9,467)

Investment in long-term deposits, net

(335)

83

83

Net cash used in investing activities

(133,631)

(195,999)

(210,600)

CASH FLOWS FROM FINANCING ACTIVITIES

Issuance of shares

7

15

30

Issuance of commercial paper

36,380

313,620

313,620

Repayment of long-term loans

(11,262)

(246,173)

(246,231)

Proceeds from long-term bank loans

20,000

20,000

Repayment of Series B, C and D Notes

(61,862)

(62,434)

(62,434)

Dividends paid (**)

(66,717)

(67,033)

(89,248)

Change in short-term bank credit and loans, net

76,316

347,215

147,475

Net cash provided by (used in) financing activities

(27,138)

305,210

83,212

Net decrease in cash and cash equivalents

(78,230)

(90,820)

(13,679)

CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD

$         197,429

$         211,108

$        211,108

CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD

$         119,199

$         120,288

$        197,429

  (*) Dividend received from affiliated companies and partnerships

$             8,540

$           14,307

$          22,321

(**)  Dividends paid during 2023 included approximately $0.5 million dividends paid by a subsidiary to non-controlling interests.

(***) Purchase of property, plant and equipment included investments in new manufacturing facilities of approximately $87 million
for the nine months ended September 30, 2024, approximately $50 million for the nine months ended September 30, 2023, and
approximately $83 million for the year ended December 31, 2023.

 

 

ELBIT SYSTEMS LTD.:

DISTRIBUTION OF REVENUES

(In millions of US Dollars)

Consolidated revenues by geographical regions:

Nine
months
ended
September
30, 2024

%

Nine
months
ended
September
30, 2023

%

Three
months
ended September
30, 2024

%

Three
months
ended September 30,
2023

%

Year
ended
December 31,
2023

%

Israel

$     1,395.1

28.5

$        730.0

16.8

$        499.0

29.1

$        230.2

15.3

$     1,167.2

19.5

North America

1,082.4

22.1

1,049.6

24.1

386.8

22.5

359.7

24.0

1,417.7

23.7

Europe

1,287.2

26.3

1,329.7

30.6

429.9

25.0

496.9

33.1

1,776.4

29.7

Asia-Pacific

858.4

17.5

968.1

22.3

315.6

18.4

314.2

20.9

1,263.8

21.2

Latin America

111.8

2.3

85.1

2.0

37.9

2.2

26.9

1.8

120.7

2.0

Other countries    

162.8

3.3

186.5

4.2

48.3

2.8

73.7

4.9

228.9

3.9

Total revenue

$     4,897.7

100.0

$     4,349.0

100.0

$     1,717.5

100.0

$     1,501.6

100.0

$     5,974.7

100.0

Consolidated revenues by segments:                                

 

Nine months
ended
September 30,
2024

Nine months
ended
September 30,
2023

Three months
ended
September 30,
2024

Three months
ended
September 30,
2023

Year ended
December 31,
2023

Aerospace

External customers

$            1,216.2

$            1,188.1

$               434.0

$               404.1

$            1,613.2

Intersegment revenue

179.1

181.8

58.2

58.0

260.1

Total

1,395.3

1,369.9

492.2

462.1

1,873.3

C4I and Cyber

External customers

558.4

490.7

198.7

171.7

668.4

Intersegment revenue

39.7

41.8

14.7

16.4

52.7

Total

598.1

532.5

213.4

188.1

721.1

ISTAR and EW

External customers

832.8

735.6

271.2

242.9

996.9

Intersegment revenue

156.0

138.9

52.7

44.2

182.5

Total

988.8

874.5

323.9

287.1

1,179.4

Land

External customers

1,144.0

884.7

402.6

330.0

1,241.0

Intersegment revenue

60.6

52.1

19.2

11.3

65.2

Total

1,204.6

936.8

421.8

341.3

1,306.2

ESA

External customers

1,146.3

1,049.9

411.0

352.9

1,455.2

Intersegment revenue

7.3

5.6

5.6

1.9

9.7

Total

1,153.6

1,055.5

416.6

354.8

1,464.9

Revenues

Total revenues (external customers and intersegment) for reportable segments

5,340.4

4,769.2

1,867.9

1,633.4

6,544.9

Less – intersegment revenue

(442.7)

(420.2)

(150.4)

(131.8)

(570.2)

Total revenues

$            4,897.7

$            4,349.0

$            1,717.5

$            1,501.6

$            5,974.7

 

Logo: https://mma.prnewswire.com/media/2017806/Elbit_Systems_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/elbit-systems-reports-third-quarter-2024-results-302309659.html

SOURCE Elbit Systems Ltd.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Lindus Health Rolls Out “All-in-One Infectious Disease CRO” Bespoke to Clinical Trials for Infectious Disease Interventions

Published

on

By

NEW YORK, Nov. 19, 2024 /PRNewswire/ — Lindus Health, the “anti-CRO” running radically faster, more reliable clinical trials for life science pioneers, has introduced their versatile contract research organization (CRO), site, and technology offering tailor-made to the execution of infectious disease trials.

Clinical development of infectious disease treatments and diagnostics must account for complexities such as diverse and evolving pathogens, seasonality and localization of study sites, and enrollment at the appropriate time during infection. Having enrolled over 5,000 patients in infectious disease studies across the US, EU, and UK, Lindus Health is well-equipped to handle the unique challenges within this therapeutic area.

Lindus Health’s latest solution for the infectious disease market segment leverages their full-spectrum CRO and site services, rooted in deep expertise in running infectious disease clinical trials. They are able to recruit diverse study populations at twice the speed of traditional CROs through their expansive recruitment capabilities, including targeted digital outreach campaigns, healthcare and community organization collaborations, and electronic health record (EHR) screening from a repository of over 30 million patients.

“Infectious disease studies require swift and adaptable approaches for execution and recruitment to keep pace with evolving pathogens and public health needs,” said Meri Beckwith, co-founder of Lindus Health. “Therefore speed of execution and access to real-time data are essential, while ensuring enrollment of diverse and representative patient populations.”

The “All-in-One Infectious Disease CRO” offers a comprehensive suite of resources and services to support infectious disease research, including:

Full-service CRO solutions: From protocol writing and study startup to close-out and data delivery, Lindus Health’s clinical operations team oversees all aspects of infectious disease trials, handling all project management and administrative responsibilities.Innovative recruitment strategies: With partnerships across primary care, urgent care, and local community groups as well as EHR screening and direct-to-patient marketing, Lindus employs advanced methods to quickly recruit diverse patient populations in infectious disease studies.Adaptable eClinical software: Citrus™, Lindus’ proprietary clinical research platform custom-built for each trial, stitches together essential tools such as clinical trial management software (CTMS), electronic data capture (EDC), telehealth, and eConsent, providing a true all-in-one solution for cohesive study management.Regulatory and industry insights: Lindus offers expertise on regulatory standards and emerging developments within infectious disease research.Comprehensive site services: Lindus’ site operations team collaborates closely with principal investigators and research staff to execute women’s health trials across single-site, multi-site, hybrid, and fully virtual environments.

“The escalating prevalence and rapid evolution of infectious pathogens present significant challenges to developing interventions to treat, detect, and protect against infectious diseases,” said Dr. Robert Langer, Institute Professor at Massachusetts Institute of Technology and Scientific Advisor to Lindus Health. “With their innovative, agile approaches to trial execution, I believe Lindus Health is well-equipped to quickly adapt and overcome these challenges as they arise.”

Lindus Health is devoted to supporting infectious disease sponsors in bringing groundbreaking treatments and diagnostics to patients and healthcare providers by streamlining all stages of the clinical trial workstream.

To learn more about the “All-in-One Infectious Disease CRO” offering, click here.

About Lindus Health

Lindus Health is an anti-CRO running radically faster and more reliable trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved  through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 30 million Electronic Health Records.

Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint by handling the end-to-end execution of clinical studies, including design, patient recruitment, clinical data capture, monitoring and project management.

To date, Lindus Health has delivered clinical trials across the US, UK and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $24M from investors including Peter Thiel, CREANDUM, Firstminute Capital, Seedcamp, Hambro Perks, Amino Collective and Calm/Storm.

Lindus Health Media Contact:
Jodi Perkins
Amendola for Lindus Health
jperkins@acmarketingpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lindus-health-rolls-out-all-in-one-infectious-disease-cro-bespoke-to-clinical-trials-for-infectious-disease-interventions-302309386.html

SOURCE Lindus Health

Continue Reading

Technology

PI’s New Expansion for Higher Electronics Manufacturing Capacities and Shorter Lead Times

Published

on

By

Investing in the future by improving ergonomics in Rosenheim, Germany facility

AUBURN, Mass., Nov. 19, 2024 /PRNewswire-PRWeb/ — PI, the market and technology leader for high-precision motion control, positioning technology, and piezo applications, has completed the construction of additional electronics production space at its Rosenheim, Germany site.

With investments of around $2.3M and a 30% increase in space, PI is strengthening its global development and production center and the economic development of the region. For 2025, another investment of $2M has been approved.

The expansion will enable production capacities of precision motion control and nanopositioning technology products to be further increased in order to meet the demands of customers from the semiconductor, photonics, laser processing, and life sciences industries.

See a variety of photonics, laser technology, and nanopositioning applications covered by PI system technologies »here.

Industries Served
Photonics, Semiconductors, Laser Technology, Microscopy, Life Sciences

PI Americas
https://www.pi-usa.us | info@pi-usa.us | (508) 832-3456

Applications Blog | Videos | X | LinkedIn

Media Contact

Ceramics Manufacturing Production Expansion, PI (Physik Instrumnente) LP, (508) 832-3456, press-release@pi-usa.us, www.pi-usa.us

Twitter

View original content to download multimedia:https://www.prweb.com/releases/pis-new-expansion-for-higher-electronics-manufacturing-capacities-and-shorter-lead-times-302308759.html

SOURCE PI (Physik Instrumnente) LP; PI (Physik Instrumnente) LP

Continue Reading

Technology

Corteva Agriscience Announces $3 Billion Share Repurchase Program

Published

on

By

Reflects Company’s Focus on Disciplined Capital Deployment

INDIANAPOLIS, Nov. 19, 2024 /PRNewswire/ — Corteva, Inc. (NYSE: CTVA) today announced that its Board of Directors authorized a new $3 billion share repurchase program. The authorization is immediately effective, does not expire, and gives management discretion in determining the conditions under which shares may be purchased.

This newly authorized program is in addition to the Company’s existing $2.0 billion program announced in September 2022, which had approximately $750 million remaining as of September 30, 2024. Shares of the Company’s common stock may be repurchased periodically in open-market or private transactions. The actual timing, number and value of shares repurchased under the Company’s authorized share repurchase program will depend on a variety of factors including the market price of Corteva common stock, general market and economic conditions, applicable legal requirements and other business considerations and uses of capital, including organic growth, dividends, and acquisitions.

“This action underscores our Board’s confidence in Corteva’s future and our commitment to returning capital to shareholders,” said Chuck Magro, Chief Executive Officer, Corteva Agriscience. “Corteva’s new share repurchase program, together with the Company’s dividend increase earlier this year, demonstrate Corteva’s strong financial outlook and commitment to a disciplined capital deployment strategy.”

For updates on the Company’s strategy, technology pipeline, and financial framework, join Corteva’s previously announced Investor Day, today at 9 a.m. Eastern Time. Registration is available on the Events and Presentations Page of the Corteva Investor Relations website. A replay will be available on the website following the webcast. 

About Corteva
Corteva, Inc. (NYSE: CTVA) is a global pure-play agriculture company that combines industry-leading innovation, high-touch customer engagement and operational execution to profitably deliver solutions for the world’s most pressing agriculture challenges. Corteva generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. With some of the most recognized brands in agriculture and a technology pipeline well positioned to drive growth, the company is committed to maximizing productivity for farmers, while working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. More information can be found at www.corteva.com.

Cautionary Statement About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “projects,” “estimates” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva’s capital allocation plans, performance outlook, and strategy are forward-looking statements. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement or other estimate, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements or other estimates is included in the “Risk Factors” section of Corteva’s Annual Report on Form 10-K, as modified by subsequent reports on Form 10-Q and Current Reports on Form 8-K.

View original content to download multimedia:https://www.prnewswire.com/news-releases/corteva-agriscience-announces-3-billion-share-repurchase-program-302309807.html

SOURCE Corteva Agriscience

Continue Reading

Trending